Cargando…
Topoisomerase II alpha and TLE3 as predictive markers of response to anthracycline and taxane-containing regimens for neoadjuvant chemotherapy in breast cancer
PURPOSE: Anthracyclines and taxanes are considered the standard for neoadjuvant chemotherapy of breast cancer, although they are often associated with serious side effects and wide variability of individual response. In this study, we analyzed the value of topoisomerase II alpha (TOP2A) and transduc...
Autores principales: | Susini, Tommaso, Berti, Barbara, Carriero, Carlo, Tavella, Ketty, Nori, Jacopo, Vanzi, Ermanno, Molino, Cecilia, Di Tommaso, Mariarosaria, Santini, Marco, Saladino, Valeria, Bianchi, Simonetta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4240193/ https://www.ncbi.nlm.nih.gov/pubmed/25484594 http://dx.doi.org/10.2147/OTT.S71646 |
Ejemplares similares
-
Expression of FGD3 gene as prognostic factor in young breast cancer patients
por: Renda, Irene, et al.
Publicado: (2019) -
Immunohistochemical Evaluation of FGD3 Expression: A New Strong Prognostic Factor in Invasive Breast Cancer
por: Susini, Tommaso, et al.
Publicado: (2021) -
TLE3 as a candidate biomarker of response to taxane therapy
por: Kulkarni, Swati A, et al.
Publicado: (2009) -
A MicroRNA Expression Signature In Taxane-anthracycline-based Neoadjuvant Chemotherapy Response
por: Zheng, Yi, et al.
Publicado: (2015) -
TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial
por: Bartlett, J M S, et al.
Publicado: (2015)